You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 1.1% |
| Div Cover | n/a | 24.1 |
| Op Mrgn | 0.0% | 38.2% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -49.3 | 3.8 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 0.0 | 1.2 |
| Price / Book value | 154.4 |
| Latest | Forecast | |
|---|---|---|
| Revenue | n/a | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 0.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | n/a | -3.40 | -3.06p | -4.5 | 0.0 | n/a | n/a | 0.0% |
| 2017-12-31 | 5.03 | 1.63 | 1.92p | 5.6 | 0.0 | n/a | n/a | 0.0% |
| 2018-12-31 | 0.10 | -4.10 | -3.45p | -3.8 | 0.0 | n/a | n/a | 0.0% |
| 2019-12-31 | n/a | -4.79 | -3.53p | -1.7 | 0.0 | n/a | n/a | 0.0% |
| Synairgen confirms start of dosing in Covid-19 trial Sharecast News | 15 Feb |
|---|---|
| Synairgen enters clinical trial deal with US government Sharecast News | 25 Jan |
| Synairgen completes recruitment for at-home Covid-19 drug trial Sharecast News | 20 Jan |
| Dosing commenced in US ACTIV-2 trial | 15-Feb-21 07:00 |
|---|---|
| Inclusion in US ACTIV-2 trial | 25-Jan-21 07:00 |
| Home trial recruitment completed | 20-Jan-21 07:00 |
| First Patient Dosing in Phase III SG018 Trial | 13-Jan-21 07:05 |
| Holding(s) in Company | 06-Jan-21 17:10 |